<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938301</url>
  </required_header>
  <id_info>
    <org_study_id>B1071001</org_study_id>
    <nct_id>NCT00938301</nct_id>
  </id_info>
  <brief_title>A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human (FIH) study is to investigate the safety, tolerability,
      pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects
      the body) of PF-04455242-01 in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single doses will include neurological assessment, vital signs and adverse event reporting during inpatient stay.</measure>
    <time_frame>Daily</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical exam</measure>
    <time_frame>Screening, End of Trial (EOT), and Follow Up (F/U)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical safety laboratory results</measure>
    <time_frame>Screening, Day 0 (D0), D2, F/U</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>Screening, D1, D2, F/U</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), area under the concentration-time curve (AUC) and terminal half-life (t1/2) .</measure>
    <time_frame>0 hr (predose) then 0.5-1 hr for the next 12 hrs postdose on D1, then 24, 36, 48, &amp; 72 hrs postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Likert and Drug Effect Questionnaire (DEQ) questionnaires</measure>
    <time_frame>0 hr (predose) then 1, 2, 3, 4, 6 ,8, &amp; 12 hrs (postdose) on D1, then 24 hrs (postdose) on D2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04455242</intervention_name>
    <description>Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PIC matching in appearance to PF-04455242 will be used to administer placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female of non-childbearing potential between the ages of 18 and 55
             years.

          -  Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg
             (&gt;110 lbs).

          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other trial procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant medical condition or allergic disease
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
             at time of screening).

          -  Use of tobacco- or nicotine-containing products within 3 months of screening or a
             positive urine or blood cotinine at screening.

          -  A positive urine drug screen. History of regular alcohol consumption exceeding 7
             drinks/week for females or 14 drinks/week for men.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1071001&amp;StudyName=A%20First%20In%20Human%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%20And%20Pharmacokinetics%20Of%20PF-04455242%20In%20Single%20Rising%20Doses%20In%20Healthy%20Ad</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>healthy volunteer, first in human, safety and tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

